Potential new therapeutic options for involvement of central nervous system in Behçet's disease (Neuro-Behçet's syndrome)

Current Rheumatology Reviews

Volumn 3, Issue 4, 2007, Pages 297-303

  Hirohata, Shunsei ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebrospinal fluid; Colchicine; Cyclosporin A; FL 6; IFN ; Infliximab; Methotrexate; MRI

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FOLIC ACID; HLA B51 ANTIGEN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISOLONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ACUTE PHASE RESPONSE; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CIGARETTE SMOKING; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; HLA TYPING; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; REVIEW; RISK FACTOR;

EID: 36349002390     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707782408973     Document Type: Review

References (28)

1. Hirohata S, Kikuchi H. Behçet's disease. Arthritis Res Ther 2003; 5: 139-46.
2. Serdaroglu P. Behçet's disease and the nervous system. J Neurol 1998; 245: 197-205.
3. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain 1999; 122: 2183-94.
4. Siva A, Altintas A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol 2004; 17: 347-57.
5. Saip S, Siva A, Altintas A, et al. Headache in Behçet's syndrome. Headache 2005; 45: 911-9.
6. Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122: 2171-82.
7. Kawai M, Hirohata S. Cerebrospinal fluid beta(2)-microglobulin in neuro-Behçet's syndrome. J Neurol Sci 2000; 179: 132-9.
8. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999; 106: 586-9.
9. Lo Monaco A, La Corte R, Caniatti L, Borrelli M, Trotta F. Neurological involvement in North Italian patients with Behçet disease. Rheumatol Int 2006; 26: 1113-9.
10. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997; 82: 12-7.
11. Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet's disease. Mod Rheumatol 17:81-2, 2007.
12. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 1998; 159: 181-5.
13. Siva A, Fresko I. Behçet's Disease. Curr Treat Options Neurol 2000; 2: 435-48.
14. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behçet disease. J Neuroophthalmol 2001; 21: 109-11.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
16. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
17. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40: 473-4.
18. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60: 637.
19. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001; 120: 995-9.
20. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-6.
21. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362-8.
22. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84.
23. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003; 62: 280-1
24. Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis. 2007; 66: 136-7.
25. Hirohata S, Kamoshita H, Taketani T. Spontaneous remission of meningoencephalitis in Behçet's disease. J Rheumatol 1989; 16: 1283-4.
26. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro- Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003; 528: 575-8.
27. Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 2005; 32: 181-3.
28. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.